Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00388674 · ClinicalTrials.gov registry record
Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 12,522
- Enrollment target
NCT00388674 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 12,522 participants.
The verdict
NCT00388674 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 12,522 participants
- Enrollment target
Study Summary
The purpose of this study is to prospectively assess the long-term outcomes (benefits and risks) associated with entecavir (ETV) therapy as compared to other antivirals approved for the treatment of chronic HBV infection. For the China substudy, patients randomized to entecavir will have safety and efficacy assessments performed during the first year of the study.
Interventions
- DRUG entecavir
- DRUG Other anti-HBV medication
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,522 participants |
| Start Date | 2006-12-18 |
| Est. Completion | 2016-10-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00388674
The ClinicalTrials.gov registry entry for NCT00388674 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 12,522 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which entecavir is the first listed.
NCT00388674 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00388674 about?
NCT00388674 is a clinical study titled "Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection". The purpose of this study is to prospectively assess the long-term outcomes (benefits and risks) associated with entecavir (ETV) therapy as compared to other antivirals approved for the treatment of chronic HBV infection. For the China substudy, patients randomized to entecavir will have safety and ...
What is the current status of trial NCT00388674?
This trial is currently completed. The enrollment target is 12,522 participants. The study started on 2006-12-18. Estimated completion is 2016-10-26.
What interventions are being tested in trial NCT00388674?
The interventions under investigation include: entecavir (DRUG), Other anti-HBV medication (DRUG).
Who is sponsoring clinical trial NCT00388674?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.